Elotuzumab is a monoclonal antibody that specifically targets Signaling Lymphocytic Activation Molecule F7 (SLAMF7), a protein expressed on myeloma and natural killer cells, to induce both immunostimulatory and direct antimyeloma cytotoxic effects. Based on preclinical evidence of enhanced antimyeloma activity when combined with a proteasome inhibitor, a phase 2 study (CA204-009T) compared the efficacy and safety of elotuzumab plus bortezomib and dexamethasone (EBd) versus bortezomib and dexamethasone (Bd) alone in patients with relapsed/refractory multiple myeloma (RRMM).1,2 One-year results of the trial demonstrated that EBd therapy significantly prolonged progression-free survival (PFS) compared with Bd (9.7 vs 6.9 months; hazard ratio [HR], 0.72; P = .09) in this patient population. Palumbo and colleagues reported on 2-year updated efficacy and safety results of the CA204-009T trial at the 2015 ASH meeting.3

In this trial, 152 eligible patients with RRMM who had failed 1 to 3 prior therapies were treated with EBd (n = 77; elotuzumab 10 mg/kg intravenously; bortezomib 1.3 mg/m2 intravenously/subcutaneously; dexamethasone 20 mg orally) or Bd (n = 75) until disease progression or unacceptable toxicity. Dexamethasone 20 mg was administered on days when elotuzumab was not administered.

In terms of efficacy, EBd treatment was associated with a significant prolongation of PFS compared with Bd treatment, with a 24% reduction in the risk of disease progression and a 25% reduction in the risk of death (HR, 0.75; P = .09); the median PFS was 9.7 months vs 6.9 months with EBd vs Bd, respectively. The 2-year PFS rate was 18% with EBd therapy compared with 11% with Bd therapy; overall response rates were similar between the 2 arms. The superiority in PFS of EBd over Bd was observed across all prespecified subgroups, including age, ISS stage at enrollment, number of lines of prior therapy, prior proteasome inhibitor use, and prior immunomodulatory therapy. Moreover, investigation of FCΥRIIIa receptor polymorphism on natural killer (NK) cells to which the Fc portion of elotuzumab binds revealed a low affinity (FF) allele and a high affinity (VV) allele; median PFS was 22.3 months in the EBd/VV group compared with 9.8 months in the EBd/FF group, suggesting a trend toward longer PFS in EBd-treated patients that are homozygous for the high affinity FCΥRIIIa V allele. Grade 3/4 adverse events were reported in 71% of the patients in the EBd arm and 60% of those in the Bd arm, including thrombocytopenia and infections. Study drug discontinuation was mainly due to disease progression (56% across treatment arms). Based on these long-term data, the authors concluded that elotuzumab combined with bortezomib and dexamethasone demonstrated significant and durable improvements in progression-free survival. The safety profile of EBd was comparable to Bd alone.

  1. Jakubowiak A, et al. J Clin Oncol. 2012;30:1960-1965.
  2. Jakubowiak A, et al. ASCO 2015. Abstract 8573.
  3. Palumbo A, et al. ASH 2015. Abstract 510.
Related Items
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Psychological Distress in Patients with Cancer Warrants Attention
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patients’ Chemotherapy-Related Side-Effect Concerns Have Evolved, But Hair Loss Remains Significant
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Increased Cancer Risk in Postmenopausal Women with Central Obesity
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patients’ Fears of Radiation Side Effects Largely Unfounded
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Netupitant plus Palonosetron Noninferior to Aprepitant plus Granisetron in Patients Receiving Highly Emetogenic Chemotherapy
Li Zhang, MD
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patient-Reported Outcomes Influence Radiation Guidelines
Alice Goodman
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Healthy Lifestyle Improves Survival in Patients with Colon Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Colorectal Cancer, Conference Correspondent
8-Week Internet-Based Psychological Intervention Reduces Stress in Patients Newly Diagnosed with Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Hair Loss Seen in 1 of 3 Women with Breast Cancer Receiving Endocrine Therapy
Alice Goodman
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Last modified: December 5, 2017